Isomorphic Labs raises $2.1B Series B
First human trials of its AI-designed drugs slip to end-2026
Confirmed
The takeaway
On 12 May 2026 Alphabet’s DeepMind spin-off Isomorphic Labs announced a $2.1B Series B led by Thrive Capital.
Status
- Claim
Confirmed
- Our reporting
- High confidence
- Importance
- 3 of 5
- Last verified
- 8 October 2026
Your AI and this story
- GPT-6 Astra12 days after its cutoff
- Claude Opus 5.5In its training data
- Gemini 4 Hydrogen42 days after its cutoff
- Grok 4.7In its training data
It is after the cutoff of GPT-6 Astra and Gemini 4 Hydrogen, and can be in the training data of Claude Opus 5.5 and Grok 4.7.
Key facts
- Series B $2.1B led by Thrive Capital; Alphabet and GV participated; new investors MGX, Temasek, CapitalG and the UK Sovereign AI Fund
- Follows a $600M first external round (2025, also led by Thrive)
- Funds to develop IsoDDE, hire across London, Cambridge (MA) and Lausanne, and advance an in-house pipeline (oncology focus reported)
- Partnered small-molecule discovery deals with Eli Lilly and Novartis
- Jan 2026 (Davos): Hassabis said Isomorphic now ‘expects to have its first clinical trials by the end of 2026’, after earlier forecasting AI-designed drugs in trials by end-2025
- Hassabis: the round is ‘a massive vote of confidence ... in our AI-first drug design approach’
- Oct 8, 2026: Bloomberg reported Isomorphic is in early talks to raise new money at a valuation of at least $40B and possibly up to $50B, five months after the $2.1B Series B; the financing had not closed (Bloomberg via Yahoo Finance)
What happened
Isomorphic Labs raised one of the largest private rounds ever for an AI drug-discovery company, three months after unveiling IsoDDE. The clinical milestone keeps slipping, though. First-in-human trials were promised for 2025, then moved to end-2026.
Why it matters
Investors are betting heavily on AlphaFold’s commercial successor. The real test is whether Isomorphic’s molecules reach patients and work, and that has not happened yet. Watch for an IND filing or first dosing by the end of 2026.
Sources
7 sources from 6 sites. Numbers match the chips in the text.
7 sources: 2 primary, 5 press
Primary
- Isomorphic Labs: Series B investment round announcementisomorphiclabs.com, official
- PR Newswire: Isomorphic Labs secures $2.1B to scale its AI drug design engineprnewswire.com, official
Press
- Fierce Biotech: Isomorphic Labs bags $2.1B Series Bfiercebiotech.com, press
- Yahoo Finance: Google-backed AI drug discovery firm pushes first trials to end-2026 (Jan 2026)finance.yahoo.com, press
- Fortune: Isomorphic Labs nears first human trials (Jul 2025)fortune.com, press
- Bloomberg: Alphabet’s Isomorphic Labs in funding talks for at least $40 billion value (Oct 8, 2026)bloomberg.com, press
- Yahoo Finance (Bloomberg): Alphabet’s Isomorphic Labs in funding talks for at least $40 billion valuefinance.yahoo.com, press
Changes
- Added Bloomberg’s Oct 8 report of talks at a $40–50B valuation
- Filed